NeuroSense Therapeutics Ltd. (NRSN)
Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 20262 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to NeuroSense Therapeutics Ltd.’s names, not what it holds today.
1 published
2 published
| Granted | Patent | Title | Field | Owner as printed |
|---|---|---|---|---|
| Sep 24, 2024 | 12,097,185 | Compositions comprising ciprofloxacin and celecoxib | Pharmaceuticals | NEUROSENSE THERAPEUTICS LTD. |
| Apr 20, 2021 | 10,980,780 | Methods and compositions of anti-inflammatory drug and dicer activator for treatment of neuronal diseases | Pharmaceuticals | NEUROSENSE THERAPEUTICS LTD. |
| Published | Application | Title | Field | Owner as printed |
|---|---|---|---|---|
| Oct 3, 2024 | 2024/0325352 | Compositions Comprising an Anti-Inflammatory Drug and a Dicer Activator for use in the Treatment of Neuronal Diseases | Pharmaceuticals | NeuroSense Therapeutics Ltd. |
| Apr 20, 2023 | 2023/0120880 | COMPOSITIONS COMPRISING CIPROFLOXACIN AND CELECOXIB | Pharmaceuticals | NEUROSENSE THERAPEUTICS LTD. · patent 12,097,185 granted from it |
| Oct 8, 2020 | 2020/0316026 | METHODS AND COMPOSITIONS OF ANTI-INFLAMMATORY DRUG AND DICER ACTIVATOR FOR TREATMENT OF NEURONAL DISEASES | Pharmaceuticals | NeuroSense Therapeutics Ltd. · patent 10,980,780 granted from it |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.